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Defective glucose-stimulated insulin secretion is the main cause of hyperglycemia in type 2 diabetes mellitus. Mutations in
HNF-1a cause a monogenic form of type 2 diabetes, maturity-onset diabetes of the young (MODY), characterized by im-
paired insulin secretion. Here we report that collectrin, a recently cloned kidney-specific gene of unknown function, is a tar-
get of HNF-1a in pancreatic b cells. Expression of collectrin was decreased in the islets of HNF-1a (2/2) mice, but was in-
creased in obese hyperglycemicmice. Overexpression of collectrin in rat insulinoma INS-1 cells or in the b cells of transgenic
mice enhanced glucose-stimulated insulin exocytosis, without affecting Ca2+ influx. Conversely, suppression of collectrin
attenuated insulin secretion. Collectrin bound to SNARE complexes by interacting with snapin, a SNAP-25 binding protein,
and facilitated SNARE complex formation. Therefore, collectrin is a regulator of SNARE complex function, which thereby
controls insulin exocytosis.Introduction
Insulin is stored in secretory granules in pancreatic b cells and is
secreted by exocytosis (Reviewed in Orci, 1974; Lang, 1999,
Rorsman and Renstro¨m, 2003). The latter process is precisely
controlled to achieve blood glucose homeostasis. Defective
glucose-stimulated insulin secretion is the main cause of hyper-
glycemia in type 2 diabetes mellitus (Reviewed in Wollheim,
2000). Maturity-onset diabetes of the young (MODY) is a clini-
cally heterogenous group of disorders accounting for 2%–5%
of type 2 diabetes. MODY is characterized by nonketotic diabe-
tes mellitus, an autosomal dominant mode of inheritance, an
onset usually before 25 years of age (frequently during child-
hood or adolescence), and a primary defect of pancreatic
b cell function (Reviewed in Fajans et al., 2001). MODY can re-
sult from mutations in any of at least six different genes that en-
code the glycolytic enzyme glucokinase (MODY2) (Froguel
et al., 1993) and five transcription factors: hepatocyte nuclear
factor (HNF)-4a (MODY1) (Yamagata et al., 1996a), HNF-1a
(MODY3) (Yamagata et al., 1996b), insulin promoter factor-1
(IPF-1) (Stoffers et al., 1997), HNF-1b (Horikawa et al., 1997),
and neurogenic differentiation 1 (NeuroD1) (Malecki et al.,CELL METABOLISM : DECEMBER 2005 $ VOL. 2 $ COPYRIGHT ª 2005 E1999). Two of these MODY genes, HNF-1a and HNF-1b, belong
to a subclass of the homeodomain family and they share a highly
conserved DNA binding domain composed of an atypical POU-
specific, a POU homeodomain and a more divergent C-terminal
transactivation domain. In most populations, mutations in the
HNF-1a gene are the most common cause of MODY (Reviewed
in Fajans et al., 2001). Mutations in the HNF-1b gene are rela-
tively uncommon, causing renal dysfunction as well as diabetes
mellitus (Horikawa et al., 1997; Bellanne-Chantelot et al., 2004).
Earlier studies indicated that HNF-1a plays an important role in
the multifactorial process of insulin secretion including glucose
transport, glycolysis and mitochondrial oxidation (Pontoglio
et al., 1998; Dukes et al., 1998; Yamagata et al., 2002; Wang
et al., 1998, 2000; Yang et al., 2002). However, the molecular
mechanisms of MODY3/MODY5 are not fully understood. The
purpose of this study was to identify novel molecule(s) involved
in the regulation of insulin secretion from b cells by screening
the downstream target genes of the HNF-1 transcription factor.
Here we report the discovery of collectrin, a recently cloned kid-
ney-specific gene of unknown function, as a novel target of
HNF-1a in pancreatic b cells and its implication in insulin exocy-
tosis.LSEVIER INC. DOI 10.1016/j.cmet.2005.11.003 373
A R T I C L EResults
Collectrin is a novel target of HNF-1
P291fsinsC (insertion of a C at codon 291in a polyC tract) is the
most common naturally-occurring mutation in the HNF-1a gene,
and this frameshift mutant acts in a dominant-negative manner
(Yamagata et al., 1998). We previously established a rat-derived
b cell line (INS-1) that can overexpress P291fsinsC-HNF-1a un-
der tight control of doxycycline (HNF1a-P291fsinsC#32 cells)
(Wang et al., 2000). To identify genes that are specifically down-
regulated by the induction of P291fsinsC-HNF-1a, we applied
the suppression subtraction hybridization technique with mRNA
extracted from doxycycline-induced or noninduced HNF1a-
P291fsinsC#32 cells. In the initial step, 376 clones from the sub-
traction library were selected for analysis. Subsequent differen-
tial screening and Northern blotting analysis identified 4 unique
genes that were down-regulated by induction of the dominant
negative mutant. DNA sequencing revealed that these 4 clones
encode collectrin/ Tmem27 (Gene bank No. NM_020976) (Fig-
ure 1A), 3-methylcholanthrene-inducible UDP-glucuronosyl-
transferase (J05132), phosphatidylcholine transfer protein-like
(PCTP-L) (NM_019990), and proliferation-associated 2G4
(Pa2g4) (NM_011119). Collectrin was originally reported as a kid-
ney specific gene, displaying increased expression in hypertro-
phic renal disease (Zhang et al., 2001). Collectrin is a putative
glycoprotein that shares homology with the C-terminal of angio-
tensin-converting enzyme-related carboxypeptidase (ACE2),
but lacks the dipeptidyl carboxypeptidase catalytic domains
and its biological function is completely unknown (Zhang
et al., 2001).
To investigate the transcriptional regulation of the collectrin by
HNF-1, we clonedw500-bp of the 50 flanking promoter region of
the rat collectrin gene. DNA sequencing revealed a high affinity
HNF-1 binding site (Tronche et al.,1997) (nucleotides 2137 to
2122, relative to the translation start codon where the A is num-
bered with +1) (Figure 1B). Screening of the genomic databank
revealed that this binding site was also conserved in the human
and mouse collectrin genes. The position of the transcriptional
start site was determined to be downstream of the binding site
by primer extension analysis (data not shown). Specific binding
of HNF-1a and HNF-1b to the putative HNF-1 binding site was
demonstrated by electrophoretic mobility shift assay (EMSA)
(Figure 1C). The promoter region of collectrin was cloned into
pGL3-luciferase vector and cotransfected into INS-1 cells with
wild-type (WT)-HNF-1a, WT-HNF-1b or P291fsinsC-HNF-1a ex-
pression vectors. WT-HNF-1a and HNF-1b dose-dependently
increased collectrin promoter activity, while the dominant nega-
tive mutant P291fsinsC-HNF-1a suppressed it (Figure 1D). Dis-
ruption of the HNF-1 binding site was associated with an 80%
reduction of promoter activity (Figure 1E).
To investigate the influence of HNF-1a on collectrin gene
expression in vivo, we measured collectrin mRNA in the islets
of HNF-1a mutant mice by real-time quantitative PCR. HNF-1a
knockout mice (Lee et al., 1998) and RIP-P291fsinsC-HNF-1a
transgenic mice (Yamagata et al., 2002) are two MODY3 mouse
models that feature impaired insulin secretion. Collectrin mRNA
was detected in pancreatic islets (see below), and its expression
was significantly reduced in the islets of RIP-P291fsinsC-HNF-
1a transgenic mice compared with their controls (Figure 1F).
Collectrin mRNA was also significantly repressed in the islets
of HNF-1a knockout mice (0.6% of WT, p < 0.01) (Figure 1F).374Therefore, both the in vitro and in vivo data indicate that collec-
trin is a direct target gene of HNF-1a.
Collectrin is expressed in pancreatic b cells
Northern blotting analysis of mouse tissues confirmed a high
level of collectrin mRNA expression in the kidney (Figure 2A).
We found that collectrin mRNA was also expressed in mouse
pancreatic islets, as well as rat INS-1 and mouse MIN6 insuli-
noma cells (Figure 2A). Although collectrin mRNA was not de-
tected in the human pancreas by a previous study (Zhang
et al., 2001), it might be expressed in human islets as is the
case in the mouse. To resolve this questions, human pancreatic
b cell rich tissue was microdissected by laser capture microdis-
section from pancreases of four cadaver donors. After RNA ex-
traction and cRNA synthesis, samples were run on Affymetrix
microarrays (GeneChip Human X3P Array); the results con-
firmed the abundant expression of collectrin in human islets.
For all of the samples, the probes for collectrin had a present de-
tection call as evaluated by the GeneChip Operating Software
(GCOS). The signal strength of collectrin for the four samples
was 535, 1535, 1116, and 1146, as determined with dChip soft-
ware. The median signal strength for the 58,876 genes on the
X3P Arrays was 42. To examine collectrin expression at the pro-
tein level, we generated an antibody against collectrin protein.
The specficity of the antibody was confirmed by a peptide com-
petition study (Figure S1 in the Supplemental Data available with
this article online). Western blots of mouse tissue extracts
showed that collectrin was expressed in pancreatic islets as
well as b cell lines (Figure 2B). In agreement with the results of
real-time quantitative PCR (Figure 1F), expression of collectrin
protein was not detected in the islets of HNF-1a knockout
mice (Figure 2B). The protein expressed in islets (43 kDa),
b cell lines (40 kDa) and kidney (38 kDa) was larger than pre-
dicted from its sequence (26 kDa). Collectrin contains two
N-linked glycosylation sites and one O-glycosylation site. Treat-
ment with N-glycosidase F and O-glycosidase led to a shift in
the mobility of collectrin to the expected size (Figure 2C), sug-
gesting that the size difference was due to glycosylation. Immu-
nohistochemical analysis of pancreatic specimens revealed that
collectrin was expressed by insulin-positive b cells in both mice
and humans (Figure 2D). Collectrin was also present in pancre-
atic a cells (data not shown), but was not detected in exocrine
cells (Figure 2D).
To investigate the potential role of collectrin in b cells, we mea-
sured its levels in mouse islets under physiological and patholog-
ical conditions. Figure 2E shows the effect of fasting and re-feed-
ing on collectrin mRNA expression in the islets. Collectrin mRNA
was significantly increased in the islets by re-feeding, suggesting
its physiological regulation. Next, we measured collectrin in two
obese animal models, i.e., high-fat diet obese C57Bl/6 (HF) mice
and KKAy mice. Both HF mice (fed for 15 weeks) and KKAy mice
(13-week-old) were obese and showed hyperglycemia com-
pared with their controls (Body weight: HF 44.16 1.7 g, control
29.16 1.7 g, KKAy 47.96 1.2 g, control 23.16 0.6 g. Blood glu-
cose levels: HF 179.6 6 3.8 mg/dl, control 141.8 6 7.5 mg/dl,
KKAy 272.2 6 38.7 mg/dl, control 120.0 6 6.7 mg/dl). In the
two mouse models, insulin secretion is increased to compensate
for insulin resistance (Winzell and Ahren, 2004; Nishizawa et al.,
2004). Plasma insulin levels were significantly increased in the
obese HF mice (9.8 6 0.9 ng/ml) compared with lean control
mice (1.96 0.6 ng/ml) and collectrin mRNA levels were elevatedCELL METABOLISM : DECEMBER 2005
Collectrin controls insulin exocytosisFigure 1. Transcriptional regulation of the collectrin gene by HNF-1
A) Effect of P291fsinsC-HNF-1a on collectrin mRNA tested by Northern blotting. Total RNA was obtained from uninduced or induced (500 ng/ml doxycycline) HNF1a-
P291fsinsC#32 cells.
B) DNA sequences of the rat, mouse, and human promoter and 50-flanking regions. The putative HNF-1 binding site is shown by a box. The asterisk denotes the transcrip-
tion start site.
C) EMSA analysis of the HNF-1 binding site in the collectrin gene promoter. DNA binding was tested using nuclear extracts of HeLa cells, which were transfected with
pcDNA3.1-HNF-1a or pcDNA3.1-HNF-1b.
D and E) The collectrin gene promoter is activated by HNF-1. INS-1 cells were cotransfected with the indicated amounts of the expression vectors as well as 0.5 mg of
pGL3-collectrin reporter and 10 ng of pRL-TK vector. (D) INS-1 cells were transfected with 0.5 mg of pcDNA3.1-HNF-1a as well as 0.5 mg of pGL3-collectrin reporter
(WT or mutant) and 10 ng of pRL-TK vector (E). Data are mean 6 SEM from three independent experiments. *p < 0.05, **p < 0.01.
F) Expression of collectrin mRNA in pancreatic islets of MODY3 model mice. Total RNA was extracted from the islets of P291fsinsC-HNF-1a transgenic mice (P291-Tg),
HNF-1a KO (2/2) mice and their control littermates for real-time RT-PCR. Data are the mean 6 SEM from three independent experiments. **p < 0.01.by 2.0-fold in the islets of HF mice (Figure 2F). Furthermore, the
protein levels were also increased 2.6-fold in the HF mice. Ex-
pression of collectrin was also significantly elevated in KKAy
mice (1.6-fold) compared with their lean controls (Figure 2G).
Thus collectrin expression was decreased in MODY3 model
mice parallel to impaired insulin secretion and was increased inCELL METABOLISM : DECEMBER 2005the obese mice. This suggests that collectrin may play a role in
insulin secretion.
Collectrin enhances insulin secretion in vitro
We generated stable transformants by transfecting an ex-
pression vector coding myc-tagged human collectrin cDNA375
A R T I C L EFigure 2. In vivo expression of collectrin mRNA under physiological and pathological conditions
A) Northern blotting analysis of collectrin gene expression. Collectrin mRNA was expressed in both pancreatic islets and b cell lines.
B)Western blotting analysis of collectrin. Collectrin was expressed in mouse pancreatic islets and b cell lines, as well as in kidney. Expression of collectrin was not detected
in the islets of HNF-1a KO mice.
C) N-glycosidase F and O-glycosidase treatment of collectrin. 0.5 mg of protein (kidney) and 4 mg of protein (MIN6, COS-7 cells and islets) were treated with N-glycosidase
F and O-glycosidase and subjected to Western blotting with anti-collectrin antibody.
D) Expression of collectrin in pancreatic b cells. Sections of C57BL6 mouse pancreas and human pancreas were immunostained with anti-collectrin antibody (green) and
anti-insulin antibody (red). The scale bar represents 40 mm.
E) Regulation of collectrin mRNA expression by nutritional status. Pancreatic islets of mice fasted for 24 hr (n = 3), or fed after fasting for 12 hr (n = 3) were subjected to real-
time RT-PCR. Results were normalized to the level of TBP mRNA. Data are the mean 6 SEM. *p < 0.05.
F) Increased collectrin expression in islets from obese HF mice. Islets were isolated from HF (implemented for 15 weeks) obese mice (n = 3) and their lean controls (n = 3) for
real-time RT-PCR and Western blotting. Results of real-time RT-PCR were normalized for the level of TBP mRNA. Data are the mean 6 SEM. *p < 0.05.
G) Increased collectrin mRNA expression in islets from KKAy mice. Islets were isolated from 13-week-old KKAy mice (n = 5) and their lean controls (n = 5) for real-time
RT-PCR. Results were normalized for the level of TBP mRNA. Data are the mean 6 SEM. *p < 0.05.(pcDNA3.1-myc-collectrin) or empty vector into INS-1 cells. The
level of exogenous collectrin mRNA expression in the stable
clones (collectrin-INS-1 cells) was 3.1- to 4.3-fold greater com-
pared to that in stable clones transfected with empty vector
(Figure 3A). The effect of overexpression of collectrin on insulin
secretion was assessed (Figure 3B). Collectrin-INS-1 cells (5 in-
dependent clones) and control clones transfected with empty
vector (5 clones) were incubated for 30 min with 2.2 to 22.2
mM glucose. Insulin secretion from collectrin-INS-1 cells was
significantly increased at stimulatory glucose concentrations
(5.5-22.2 mM) compared with that from control cells, whereas
there was no difference at 2.2 mM glucose. The increase of insu-
lin secretion was not due to altered insulin synthesis, since the376insulin content of collectrin-INS-1 cells and control cells was
similar (Figure 3C). We then suppressed the expression of en-
dogenous collectrin in INS-1 and MIN6 cells by small inhibitory
RNA (siRNA) (Figure 3D). Suppression of endogenous collectrin
led to 39% (INS-1) and 44% (MIN6) decrease in the expression of
collectrin, while insulin secretion stimulated by 22.2 mM glucose
was significantly inhibited by 25% in INS-1 cells and 33% in
MIN6 cells. These results suggest that collectrin has an impor-
tant role in enhancing glucose-stimulated insulin secretion.
In b cells, an increase of the ATP/ADP ratio due to glucose
metabolism closes ATP-sensitive potassium channels, leading
to membrane depolarization, calcium influx, fusion of insulin-
containing secretory granules with the plasma membrane, andCELL METABOLISM : DECEMBER 2005
Collectrin controls insulin exocytosisFigure 3. Collectrin augments insulin secretion by
INS-1 cells
A)Northern blotting analysis of collectrin expression in
stable clones. INS-1 cells were transfected with
pcDNA3.1-myc-collectrinor theemptypcDNA3.1vec-
tor. Ten stable clones (collectrin-INS-1 clones 2, 8, 21,
101, and 117; vector control clones 54, 56, 60, 65, and
71) were obtained. The gels were scanned and quanti-
fied.
B) Glucose-stimulated insulin secretion from collec-
trin-INS-1 cells (clones 2, 8, 21, 101, and 117) (solid
bars) and control INS-1 cells (54, 56, 60, 65, and 71)
(open bars). Insulin secretion was assessed in triplicate
for eachclone.Dataare the mean6SEM.N.S.,notsig-
nificant. *p < 0.05 compared with control INS-1 cells.
C) Insulin content of collectrin-INS-1 cells and control
INS-1 cells. Collectrin-INS-1 cells (5 clones) and INS-1
cells (5 clones) were platedon 6-wellplatesata density
of 53 105 cells. Insulin content was measured in tripli-
cate for each clone. Data are the mean6 SEM. N.S.,
not significant.
D) Suppression of collectrin expression by siRNA re-
duces glucose-stimulated insulin secretion. INS-1
and MIN6 cells were transfected with specific rat and
mouse collectrin siRNA or control siRNA. Expression
of endogenous collectrin was determined by Western
blotting. The secretory response of insulin to glucose
was reduced by collectrin-specific siRNA. Data are
the mean 6 SEM. **p < 0.01 compared with the con-
trol.
E) Changes of the [Ca2+]i in response to 27.8 mM glu-
cose and 20 mM KCl in collectrin-INS-1 cells (clone
2) and control INS-1 cells (clone 60). There is no signif-
icant difference of the area under the curve (AUC) for
clone 2 and clone 60. Data are the mean6 SEM.
F) Insulin secretion in response to 60 mM KCl. High K+-
induced insulin secretion was significantly greater in
collectrin-INS-1 cells (5 clones) compared with control
cells (5 clones). Insulin secretion was tested in triplicate
for each clone. Data are the mean6 SEM. *p < 0.05.
G) Effect of collectrin on glucose-stimulated secretion
of growth hormone from INS-1 cells. INS-1 cells were
transfectedwithLacZ,Wt-collectrin,ormutant-collectrin
(0.5 mg) and pcDNA3-hGH (0.5 mg). Values are shown
as the percentage of growth hormone secretion rela-
tive to that in control cells (LacZ). Data are the
mean6 SEM. *p < 0.05.the secretion of insulin (Wollheim, 2000, Rorsman & Renstro¨m,
2003). To determine how collectrin enhances insulin secretion,
we first measured [Ca2+]i in collectrin-INS-1 clones and control
clones. Glucose stimulation lead to a similar increase of [Ca2+]i
in both types of cells (Figure 3E). The similar response of
[Ca2+]i suggested that collectrin acts on steps beyond Ca
2+ in-
flux in the process of insulin secretion. High K+-induced depolar-
ization evokes Ca2+-dependent insulin release from b cells. Like
glucose, KCl stimulated insulin secretion was more pronounced
in collectrin-INS-1 cells than in control cells (Figure 3F). Pancre-
atic b cells contain at least three functionally distinguishable
pools of insulin granules: undocked, docked, and primed readily
releasable pool (RRP) (Reviewed in Rorsman and Renstro¨m,
2003). Because the amount of exocytosis induced by K+ stimu-
lation is considered to represent the size of the RRP (Reviewed
in Rorsman and Renstro¨m, 2003), the enhanced response to K+
stimulation suggested that overexpression of collectrin may in-
crease the size of the RRP.
The role of collectrin in the exocytotic pathway was further
explored by transiently cotransfecting INS-1 cells with WT-CELL METABOLISM : DECEMBER 2005collectrin, deletion mutants of collectrin (DC-, and DN-collectrin),
or LacZ expression vector together with human growth hormone
(hGH) expression vector (Figure 3G, left panel). In transfected
cells, hGH is targeted to insulin-containing secretory granules,
and the hormone allows the monitoring of the exocytotic pro-
cess (Coppola et al., 1999; Iezzi et al., 2000). Transfection of
WT-collectrin significantly increased glucose-stimulated hGH
secretion compared with that of LacZ. However, augmented
hGH secretion was not observed when mutant collectrin was
transfected into the cells (Figure 3G, right panel). These results
emphasize the role of collectrin in the process of exocytosis in
INS-1 cells.
Collectrin is located on the limiting membrane
of insulin granules
We next investigated the subcellular distribution of collectrin in
collectrin-INS-1 cells. Immunofluorescence microscopy showed
that collectrin was localized in the cytoplasm of INS-1 cells.
Double staining for collectrin and insulin showed that both
signals were often colocalized in the cells (Figure 4A). To377
A R T I C L EFigure 4. Intracellular localization of collectrin in INS-1 cells
A) Intracellular localization of myc-tagged collectrin. Collectrin-INS-1 (upper panels) and control INS-1 cells (lower panels) were double stained with an anti-insulin antibody
(Alexa 594 label, red) and an anti-myc antibody (Alexa 488 label, green) for examination by confocal microscopy. The scale bar represents 5 mm.
B)Ultrathin sections of INS-1 cells were immunolabeled with a rabbit antibody for collectrin. Gold particles were found on the periphery of insulin granules (arrow) as well as
microvesicles (arrowhead). The scale bars represent 500 nm (left) and 100 nm (right).substantiate the findings in light microscopy, we performed
immunogold electron microscopy. When ultrathin sections of
INS-1 cells were immunolabeled with anti-collectrin antibody,
immunogold particles were found on the periphery of large
secretory granules as well as microvesicles (Figure 4B). This in-
dicates the localization of collectrin to the limiting membrane of
insulin granules.
Collectrin increases insulin exocytosis in vivo
The following experiments assessed the role of collectrin in insu-
lin secretion in vivo. We generated transgenic mice with b cell
targeted overexpression of collectrin (RIP-collectrin Tg). Collec-
trin protein in the pancreatic islets of the transgenic mice was
2.3-fold elevated relative to endogenous collectrin by Western
blotting (Figure 5A). The body weight and random blood glucose
levels did not differ between RIP-collectrin Tg mice and control
mice (data not shown). However, glucose tolerance tests (GTT)
revealed that blood glucose levels were significantly lower in the
Tg mice than in controls at 30 min, 60 min, and 120 min after
a glucose load (Figure 5B). The acute phase of insulin secretion378(15 min after glucose load) was significantly increased by
1.6-fold in Tg mice (Tg: 781.5 6 79.1 pg/ml; control: 496.1 6
131.1 pg/ml, p < 0.05) (Figure 5C). Immunostaining of pancreatic
sections with an antibody against insulin revealed a normal islet
architecture in the RIP-collectrin Tg mice (Figure 5D). Likewise,
there was no significant difference in the b cell area per pancreas
between Tg and control mice as revealed by quantitative analy-
sis (Figure 5D). In agreement with the results obtained in INS-1
cells, the insulin response to high glucose was increased in col-
lectrin-Tg islets (Figure 5E). Cumulative glucose-induced insulin
secretion from RIP-collectrin Tg islets was significantly aug-
mented by 2.8-fold at 30 min compared with control islets
(Figure 5E).
To investigate the mechanism underlying the increase in glu-
cose-stimulated insulin secretion by collectrin-Tg islets, we di-
rectly measured the exocytosis of insulin granules and the rise
in cytosolic Ca2+ in response to glucose stimulation by 2-photon
excitation imaging. This novel morphological technique enables
the precise monitoring of individual exocytotic events and other
relevant parameters in a defined area, of intact islets (TakahashiCELL METABOLISM : DECEMBER 2005
Collectrin controls insulin exocytosisFigure 5. Collectrin increases insulin exocytosis in
vivo
A) Generation of transgenic mice overexpressing
collectrin in b cells (RIP-collectrin Tg). Expression
of collectrin in the islets of Tg mice caused a 2.3-
fold increase compared with the islets of control
mice.
B and C) Glucose-stimulated insulin secretion in
RIP-collectrin Tg mice. Blood glucose levels in Tg
mice (closed circles: n = 5) at 30, 60, and 120 min af-
ter a glucose load were significantly lower than in
control mice (open circles: n = 5) (B) The serum insu-
lin level of Tg mice at 15 min after a glucose load was
significantly increased compared with control mice
(C). Data are the mean 6 SEM. *p < 0.05, **p < 0.01.
D) Immunostaining of pancreatic sections from
20- to 24-week-old Tg and control mice. The b cell
area is shown as a percentage of the total pancreatic
area. Data are the mean6 SEM for 3 mice. The scale
bar represents 100 mm.
E) Insulin secretory response to glucose in perifused
islets of Tg mice. The insulin response to 22 mM glu-
cose was significantly increased in Tg islets. Total
insulin secretion from perifused isolated Tg islets
and control islets was calculated from the area under
the curve (AUC) (right). Data represent the mean 6
SEM of three experiments on each genotype. *p <
0.05.
F) Response of [Ca2+]i to glucose in Tg islets.
Changes of [Ca2+]I in response to 20 mM glucose
were measured in islets with fura-2 using two-photon
excitation imaging in pancreatic b cells and repre-
sented as (F0-F)/F0, where F0 and F represent resting
fluorescence and the fluorescence after stimulation,
respectively. The (F0-F)/F0 response to glucose stim-
ulation was calculated and the mean 6 SEM is pre-
sented.
G) Exocytosis in response to 20 mM glucose. Exocy-
tosis from Tg islets (n = 5, red) and control islets (n =
5, black) was detected with 2-photon microscopy.
Data are the mean 6 SEM. **p < 0.01.
H) Exocytosis evoked by photolysis of the caged-
Ca2+ compound. Data represent the mean 6 SEM
of 4 experiments on each genotype. *p < 0.05.et al., 2002; Kasai et al., 2005). The glucose-induced increase of
Ca2+ measured with Fura-2 was similar in collectrin-Tg mice and
control mice (Figure 5F). When the number of exocytotic events
was visualized with a solution containing a fluid-phase tracer
(sulforhodamine B), exocytotic events during a period of 10
min of 20 mM glucose stimulation were significantly increased
in RIP-collectrin Tg islets (Tg: 91.7 6 23.1 events/2,000 mm2;
control: 55.7 6 7.1 events/2,000 mm2, p < 0.01) (Figure 5G).
We also directly examined the role of collectrin in Ca2+-
dependent insulin exocytosis by photolysis of a caged-Ca2+
compound (NP-EGTA). Uncaging leads to a large, spatially ho-
mogenous and rapid increase in [Ca2+]i in the islets as well asCELL METABOLISM : DECEMBER 2005triggering insulin exocytosis (Takahashi et al., 2004). We found
that insulin exocytosis evoked by photolysis of the caged-
Ca2+ compound was also increased in Tg islets (Figure 5H).
Taken together, these results clearly demonstrate that collectrin
increases insulin secretion by enhancing exocytosis.
Collectrin increases exocytosis by interaction
with snapin
To further elucidate the molecular relationship between collec-
trin and exocytosis, we searched for a molecule that interacts
with collectrin by yeast two-hybrid screening using collectrin
as the bait. After screening more than 107 independent clones,379
A R T I C L EFigure 6. Effect of interaction between collectrin
and snapin on exocytosis
A) Northern blotting analysis of snapin gene expres-
sion.
B) Interaction of collectrin with snapin in vivo.
pcDNA3.1-myc-collectrin and/or pcDNA3.1-HA-snapin
expression vectors were cotransfected into HEK 293
cells. The interaction was evaluated by immunopre-
cipitation with anti-HA antibody or anti-myc anti-
body, followed by immunoblotting.
C) Interaction of collectrin in vitro. WT-collectrin,
DN-collectrin, or DC-collectrin was translated in vitro
and labeled with 35S. Binding of collectrin to GST-
snapin or GST alone was evaluated.
D) Intracellular localization of HA-tagged snapin.
Collectrin-INS-1 cells were transfected with
pcDNA3.1-HA-snapin. Cells were double-stained
with anti-HA antibody (Alexa 594 label, red) and
anti-myc antibody (Alexa 488 label, green). The scale
bar represents 5 mm.
E and F) Influence of functional interaction between
collectrin and snapin on glucose-stimulated secre-
tion of growth hormone. INS-1 cells were transfected
with collectrin (0.5 mg) or snapin (0.5 mg) expression
vector plus pcDNA3-hGH (0.5 mg) (n = 10). The total
amount of DNA was adjusted to 1.5 mg (E) and
3.5 mg (F) using pcDNA3.1-lacZ. INS-1 cells were
transfected with the WT or DN collectrin and snapin
expression vectors plus pcDNA3-hGH (n = 3) (F). Val-
ues show the percentage of growth hormone secre-
tion relative to control. Data are the mean 6 SEM.
NS: not significant, *p < 0.05, **p < 0.01.
G) Coimmunoprecipitation of collectrin with SNAP-
25, VAMP2, and syntaxin 1. Collectin-INS-1 cell ly-
sates were immunoprecipitated with anti-myc anti-
body. SNAP-25, VAMP2, and syntaxin 1 were de-
tected by immunoblotting.
H) Effect of collectrin on SNARE complex formation.
Lysates of collectrin-INS-1 cells or control INS-1
cells were immunoprecipitated with an anti-syntaxin
1 antibody and the amount of VAMP2 bound to syn-
taxin 1 was determined by immunoblotting with an
anti-VAMP2 antibody. Association of syntaxin 1
with VAMP2 is increased in collectrin-INS-1 cells.we found 7 clones that strongly interacted with collectrin in
yeast, among these, 3 clones encoded snapin. Snapin is a 15
kDa protein containing the predicted coiled-coil domain in the
C-terminal half (Ilardi et al., 1999). Snapin has been reported
to bind to synaptic soluble N-ethylmaleimide-sensitive-factor
attachment protein receptor (SNARE) complexes (reviewed in
Chen and Scheller, 2001; Jahn et al., 2003). Through direct inter-
action with SNAP-25, snapin is implicated in calcium-triggered
vesicle fusion by regulating the association between the SNARE
complex and the putative Ca2+-sensor synaptotagmin (Ilardi
et al., 1999). Although snapin was initially regarded as a brain-
specific molecule (Ilardi et al., 1999), subsequent studies have
revealed its ubiquitous expression (Buxton et al., 2003). North-
ern blotting analysis showed that snapin mRNA was also ex-
pressed in pancreatic islets, as well as MIN6 and INS-1 cells
(Figure 6A).
Subsequently we evaluated the specificity of the interaction
between collectrin and snapin both in vivo and in vitro. As shown
in Figure 6B, HA-snapin was able to coimmunoprecipitate myc-
collectrin and conversely myc-collectrin also associated with380HA-snapin in 293 cells. A direct interaction between collectrin
and snapin was verified by the GST-pull-down assay. GST-sna-
pin bound to WT-collectrin and DN mutant collectrin, but not to
DC mutant collectrin (Figure 6C), indicating direct binding of
snapin to the C-terminal domain of collectrin. Next, collectrin-
INS-1 cells were transfected with HA-tagged snapin expression
vector and the intracellular localization of snapin was investi-
gated by immunofluorescence microscopy using anti-HA anti-
body. Double staining for collectrin and snapin revealed that
both signals were frequently colocalized in the cytoplasm of
INS-1 cells (Figure 6D).
To investigate the functional relevance of this interaction, INS-1
cells were transiently transfected with collectrin and/or snapin
expression vectors together with the hGH expression vector,
after which glucose-stimulated hGH secretion was measured
(Figure 6E). Snapin alone did not increase hGH secretion, while
cotransfection of collectrin and snapin significantly augmented
hGH release (Figure 6E). Although DN-collectrin binds to
snapin, the mutant did not augment glucose-stimulated hGH se-
cretion (Figures 6C and 3G). Cotransfection of DN-collectrinCELL METABOLISM : DECEMBER 2005
Collectrin controls insulin exocytosissignificantly suppressed the augmented hGH secretion by col-
lectrin and snapin (Figure 6F). These results strongly suggest
that collectrin is implicated in exocytosis by interacting with sna-
pin.
We next investigated whether collectrin was able to bind to
the SNARE complex. Lysates from collectrin-INS-1 cells were
subjected to immunoprecipitation using anti-myc antibody, af-
ter which the precipitates were immunoblotted with SNAP25
and VAMP2 antibodies. As shown in Figure 6G, SNAP-25 and
VAMP2 were coimmunoprecipitated with collectrin, indicating
the formation of a collectrin/SNARE complex in vivo. Direct
binding of collectrin to SNAP-25, syntaxin 1 and VAMP2 was
subsequently examined by the GST-pull down assay. While sna-
pin bound to GST-collectrin, SNAP-25, syntaxin 1 and VAMP2
did not (data not shown), indicating that collectrin binds to
SNARE proteins indirectly, most likely by interacting with sna-
pin. Finally, we explored the effect of collectrin overexpression
on SNARE complex formation. Lysates from collectrin-INS-1
cells and control INS-1 cells were subjected to immunoprecipi-
tation with anti-syntaxin 1 antibody and the precipitates were
immunoblotted with anti-VAMP2 antibody. As shown in Fig-
ure 6H, VAMP2 immunoreactivity was increased in precipitates
from collectrin-INS-1 cells relative to control cells, indicating
that collectrin facilitates formation of the SNARE complex.
Discussion
Collectrin was originally discovered as a renal collecting duct-
specific glycoprotein with an unknown function (Zhang et al.,
2001). In the present study, we clarified that collectrin is a novel
target of HNF-1 in pancreatic b cells and that it controls insulin
exocytosis. In addition, we demonstrated that collectrin binds
directly to snapin and forms a complex with SNARE proteins.
Snapin has been suggested to potentiate the interaction of syn-
aptotagmin with the SNARE complex during the release of syn-
aptic vesicles (Ilardi et al., 1999). In adrenal chromaffin cells,
snapin is thought to facilitate formation of the SNARE complex,
which is stabilized by protein kinase A-mediated phosphoryla-
tion of snapin (Chheda et al., 2001). Although the precise role
of snapin in the process of exocytosis remains unclear (Vites
et al., 2004), collectrin may act in concert with snapin to increase
SNARE complex formation. We found that 2.3-fold overexpres-
sion of collectrin in b cells lead to 2.8-fold enhancement of glu-
cose-stimulated insulin secretion from perifused pancreatic is-
lets (Figure 5E), while 39%–44% suppression of collectrin
expression in insulinoma cells reduced insulin secretion by
25%–33% (Figure 3D). These results suggest an important
role of collectrin in insulin secretion. Investigation of collectrin
knockout mice will enhance our understanding of the physiolog-
ical significance of this molecule in the process of exocytosis.
Mutations in the HNF-1a and HNF-1b genes cause MODY,
which is characterized by impaired insulin secretion (Reviewed
in Fajans et al., 2001). Taken together, it is possible that impaired
insulin secretion in patients with MODY is due, at least in part, to
reduced expression of collectrin. HNF-1a affects multiple steps
during the process of glucose-stimulated insulin secretion. For
example, it has been reported that GLUT2, insulin, E-cadherin
and IGF-1 are target genes of HNF-1a (Pontoglio et al., 1998;
Dukes et al., 1998; Wang et al., 1998, 2000; Yamagata et al.,
2002; Yang et al., 2002). We do not claim that collectrin is the
only target of HNF-1 in islets and it is quite possible that de-CELL METABOLISM : DECEMBER 2005creased collectrin expression alone may not explain all the phe-
notypes in the HNF-1a (2/2) mice. However, we believe that
collectrin is one of the important players together with GLUT2,
insulin, E-cadherin and IGF-1 in impaired insulin secretion in
MODY3 patients. A therapeutic strategy that increases collectrin
expression might be useful in MODY3 patients.
We also found that collectrin expression was enhanced in the
islets of HF mice and KKAy mice. Obesity leads to the develop-
ment of insulin resistance and hypersecretion of insulin by
b cells. This compensatory hypersecretion of insulin not only re-
flects expansion of the b cell mass, but is also due to altered
b cell function (Cavaghan et al., 2000). Since collectrin enhances
insulin secretion, the observed increased expression in obese
animals may participate in b cells adaptation to insulin resis-
tance. It would be interesting to study the expression of collec-
trin in animal models with different levels of insulin resistance
and diabetes mellitus. The mechanism by which collectrin ex-
pression is increased in the islets of obese mice is presently un-
known. Although HNF-1a regulates transcription of the collec-
trin gene, expression of HNF-1a mRNA was not increased in
the islets of HF mice (K.F. and K.Y., unpublished data), suggest-
ing the existence of another regulatory mechanism. Chronic ex-
posure of b cells to free fatty acids and hyperglycemia associ-
ated with obesity and diabetes could however contribute to
the increment of collectrin expression.
In conclusion, we identified collectrin as a novel molecule that
controls insulin exocytosis. Our results demonstrate that collec-
trin favors the formation of SNARE complexes and therefore ex-
tent the list of molecules implicated in the regulation of exocyto-
sis. The correlation between islet expression of collectrin and
insulin hyper- and hypo-secretory states emphasizes the key
role of collectrin in b cell function. Consequently, collectrin
may be a potential target for the treatment of diabetes associ-
ated with impaired insulin secretion.
Experimental procedures
Suppression subtraction hybridization and differential screening
INS-1 cells overexpressing the dominant negative mutant P291fsinsC-HNF-
1a under control of the reverse tetracycline-dependent transactivator
(HNF1a-P291fsinsC#32) have been described previously (Wang et al.,
2000). Total RNA was prepared using Trizol reagent (Invitrogen, San Diego,
CA) and poly(A)+ mRNA was subsequently isolated with a poly(A) RNA isola-
tion kit (Qiagen, Hilden, Germany). Suppression subtraction hybridization
(SSH) was performed using a PCR Select cDNA Subtraction Kit (BD Bio-
sciences Clontech) according to the protocol of the manufacturer. Driver
cDNA was synthesized from the mRNA of HNF1a-P291fsinsC#32 cells in-
duced with doxycycline for 48 hr and tester cDNA was synthesized from
the mRNA of uninduced HNF1a-P291fsinsC#32 cells. The subtracted cDNAs
were inserted into the pGEM-T Easy vector (Promega, Madison, WI) and
transformed into Escherichia coli DH5a to yield an SSH library. A PCR-Select
Differential Screening Kit (Clontech Laboratories, Palo Alto, CA) was used to
screen the differentially expressed products according to the instructions of
the manufacturer.
Cloning of the 50-flanking promoter region of rat collectrin
The 50-flanking promoter region of the rat collectrin gene was cloned with
a Genome Walker Kit (Clontech) according to the protocol of the manu-
facturer using the following primers: 50-TCATCGGGCACCTGGACACTTTC
AC-30 and 50-GTTCTGTTGATTCAGCTGGCTTTTC-30.
Reporter gene analysis
The human collectrin promoter containing a putative HNF-1 binding site was
amplified by PCR with the forward primer 50-GACAGGACTCAGATCTTC
CCATCA-30 (underlined nucleotides indicate the cloned BglII site) and the381
A R T I C L Ereverse primer 50-CAACATTCTTTCAAGCTTGAAAAC-30 (underlined nucleo-
tides indicate the cloned HindIII site). The PCR products were subcloned into
the pGL3 basic reporter vector (Promega) to generate pGL3-collectrin. The
HNF-1a2binding site (5-GTTAATCATTAA-3) was altered to 5-GTTGGCTAC
CAG-3 by PCR. INS-1 cells were transfected for 3 hr in OPTI-MEMI (Life
Technologies, Rockville, MD) with the indicated amounts of expression vec-
tors and the reporter gene (as described in the figure legend) together with
pRL-TK (the internal control) using Lipofectamine PLUS reagent (Life Tech-
nologies) as described previously (Yamagata et al., 1998).
Electrophoretic mobility shift assay
The pcDNA3.1-WT-HNF-1a or pcDNA3.1-WT-HNF-1b expression vector
(Yoshiuchi et al., 2002) was transfected into HeLa cells and nuclear protein
was extracted. Then 2 mg of protein was incubated with a 32P-labeled oligo-
nucleotide containing the HNF-1 binding site of the human collectrin gene (50-
GATGGGTGTTAATCATTAAACCTTT-30). The DNA-protein complexes were
separated by 5% polyacrylamide gel electrophoresis.
Northern blotting and real-time RT-PCR
Northern blotting was carried out as described previously (Iwahashi et al.,
2002). For real-time quantitative PCR, pancreatic islets were isolated as de-
scribed previously (Yamagata et al., 2002) and total RNA was extracted. Col-
lectrin cDNA was synthesized from the total RNA and was tested in triplicate
with an ABI PRISM 7900 (Applied Biosystems, Foster City, CA) using the fol-
lowing specific primers and a fluorescence-labeled probe: 50-ATTCGGTGTG
ATATTTTGCATTGT-30, 50-TCCAGGTGGTCCTTTGTTGTT-30, and 50-(FAM)-
TCCGGCAACGCAGAA-30. The primers and the probe for the TATA box bind-
ing protein (TBP) (endogenous control) were purchased from ABI.
Human pancreatic tissue, laser capture microdissection,
and microarray analysis
Human pancreases from four donors were obtained from the New England
Organ Bank (NEOB) with informed consent to use for research and were pro-
cessed in the Islet Cell Resource Center of the Joslin Diabetes Center. After
trimming away excess fat and connective tissue, small pieces of pancreas
were excised, placed in cryomolds, embedded in Tissue-Tek OCT medium
(Sakura Finetek U.S.A., Torrance, CA), immediately frozen in chilled isopen-
tane, and stored at280ºC. Frozen pancreas tissues were sectioned at 8 mm
in a cryostat, mounted on uncoated glass slides (Fisher Scientific, Pittsburg,
PA), and stored at 280ºC until the microdissection.
Laser Capture Microdissection (LCM) was performed as described previ-
ously. The frozen pancreatic sections were dehydrated completely air-dried
and LCM was performed using PixCell II Laser Capture Microdissection Sys-
tem (Arcturus Engineering, Mountain View, CA). Laser capture was per-
formed under direct microscopic visualization by melting of selected cells
onto a thermoplastic film mounted on optically transparent LCM caps (Arctu-
rus). The b cell rich tissue was identified by its autofluorescence. Total RNA
was extracted from microdissected samples using the PicoPure RNA Isola-
tion Kit (Arcturus). Genomic DNA contamination was removed by incubation
with 14 units of DNase I for 15 min at room temperature (RNase Free DNase
Set, Qiagen). After extraction total RNA was amplified using the RiboAmp HS
RNA Amplification Kit (Arcturus). Amplified RNA (1.5 mg) obtained from each
sample was converted into double-stranded cDNA using the RiboAmp HS
RNA Amplification Kit (Arcturus). Double stranded cDNA products were pu-
rified by filtering through the MiraColTM Purification Columns (Arcturus). Bio-
tinylated cRNA was generated from purified cDNA samples by in vitro tran-
scription reaction using a BioArray High Yield RNA Transcript Labeling Kit
(Enzo Diagnostics, Farmingdale, NY). RNA products were then purified using
the MiraColTM Purification Columns (Arcturus) and fragmented to nucleotide
stretches of 30-200 nucleotides. The biotinylated fragmented RNA was hy-
bridized to GeneChip Human X3P Array (Affymetrix, Santa Clara, CA). After
hybridization the chips were washed in a GeneChip Fluidics Station 400 (Af-
fymetrix) and stained with streptavidin-phycoerythrin, the signal was ampli-
fied by biotinylated anti-streptavidin and analyzed by a GeneChip Scanner
3000 using the GeneChip Operating Software (GCOS) (Affymetrix). The array
data were normalized using the DNA-Chip Analyzer (dChip) software. The
program performs a model-based expression analysis that allows probe-
level analysis on multiple arrays and normalizes the array data to a common
baseline array having the median overall brightness, as measured by the me-
dian CEL intensity in an array (Li and Wong, 2001).382Immunoblotting, immunohistochemistry, and immunofluorescence
studies
Rabbit anti-collectrin antibody was raised against a synthetic peptide (NDAFM-
TEDERLTPL) corresponding to amino acids 209 to 222 of human collectrin.
Western blotting analysis and immunohistochemistry were performed as
described previously (Yamagata et al., 2002). Guinea pig anti-porcine insulin
antibody (1:5,000) (Dako Corporation, CA) and rabbit anti-collectrin antibody
(1:200) were used as the primary antibodies. Human pancreatic sections
were obtained from SuperBio Chips (Seoul, Korea). For the deglycosylation of
glycoproteins, proteins were treated with N-glycosidase F (Roche, IN) and
O-glycosidase (Roche) before Western blotting according to the manufac-
turer’s instructions. For the immunofluorescence study, INS-1 cells were grown
on Lab-Tek II chamber slides (Nunc-Immuno Plate, Roskilde, Denmark) for
72 hr. Then the cells were fixed in 4% paraformaldehyde and permeabilized
with 0.1% Triton X-100 in phosphate-buffered saline containing 1% bovine se-
rum albumin (BSA). Guinea pig anti-porcine insulin antibody (1:100), mouse
anti-myc antibody (1:200) (Medical Bioscience Laboratories), and rabbit anti-
HA antibody (1:200) (Medical Bioscience Laboratories) were used as the pri-
mary antibodies. Immunofluorescence was viewed under a laser scanning con-
focal microscope (LSM510; Carl Zeiss, Eching, Germany).
Generation of stable INS-1 cell lines overexpressing collectrin
The nucleotide sequence encoding the myc epitope was introduced into hu-
man collectrin cDNA in frame after the signal sequence by PCR. INS-1 cells
were transfected with the pcDNA3.1-myc-collectrin expression plasmid or
empty vector using Lipofectamine PLUS reagent. Stable transformants (col-
lectrin-INS-1 cells) were obtained by cloning the colonies under selection
with 400 mg/ml neomycin (Sigma-Aldrich, St. Louis, MO).
Insulin secretion and cellular insulin content
Insulin secretion from INS-1 cells was measured over a period of 30 min, in
Krebs-Ringer- bicarbonate-4-(2-hydroxyethyl)-1-piperazine ethanesulfonic
acid (HEPES) buffer (KRBH; 140 mM NaCl, 3.6 mM KCl, 0.5 mM NaH2PO4,
0.5 mM MgSO4, 1.5 mM CaCl2, 2 mM NaHCO3, 10 mM HEPES, and 0.1%
BSA), containing the indicated stimulators. The insulin content was deter-
mined after extraction with acid ethanol as described previously (Yamagata
et al., 2002). Insulin was detected by using a Glazyme insulin enzyme immu-
noassay kit (Wako Pure Chemical Industries, Osaka, Japan).
SiRNA knockdown of collectrin expression
For siRNA-mediated knockdown of collectrin expression, nucleotides 229-
253 (GenBank AF178086) of rat collectrin cDNA (50-GCAAUGUAACCCAGA
GAGUGUCAUU-30) and nucleotides 344-368 (GenBank AF178085) of mouse
collectrin cDNA (50-GGUCACGGACCCUUCCAACAAUUAU-30) were used as
the target sequences. Transfection of siRNA (50 nM) into INS-1 cells and
MIN6 cells was performed by using RNAiFect reagent (Qiagen) according
to the protocol of the manufacturer. The following sequences were used as
control siRNA: 50-GGUCACGGACCCUUCCAACAAUUAUdTdT-30 for mouse
collectrin and 50-GCAAAUGACCCAGAGUGUGCUAAUUdTdT-30 for rat col-
lectrin. SiRNA duplex was synthesized by Invitrogen. After incubation for
48 hr, Western blotting and insulin secretion experiments were performed
as described above.
Measurement of the intracellular calcium concentration
INS-1 cells were cultured on glass-bottomed culture dishes (MatTek) for
2 days. Subsequently, the cells were loaded with 2 mM Fura-2 acetoxymethyl
ester (Dojin Chemicals Co., Kumamoto, Japan) for 60 min at 37ºC. Changes
of [Ca2+]i were determined as the ratio of emitted light intensity (detected at
510 nm) after excitation at either 340 or 380 nm.
Growth hormone secretion assay
Mutant collectrin cDNA was generated by PCR and subcloned into
pcDNA3.1. To construct N-terminal (DN-collectrin) and C-terminal (DC-col-
lectrin) deletion mutants, the following primers were used (DN: 50-GGATCC
ATGGAACAAAAACTCATCTCAGAAGAGGATCTGCCCATCTGGATTATTA
TATTTGGT-30 and 50-GAATTCTCAGAGAGGGGTGAGCCTCTCATC-30, DC:
50-GGATCCATGTTGTGGCTGCTCTTTTTTCTG-30 and 50-GAATTCCTAGAT
CCCTGATAAAATCAGTAGTGC-30 (the underlined nucleotides indicate the
cloning sites and the myc tag sequence is shown in italics). INS-1 cells
were cotransfected with a GH expression vector (pcDNA3-hGH),CELL METABOLISM : DECEMBER 2005
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amine PLUS reagent. At 48 hr after transfection, cells were preincubated in
glucose-free KRBH for 15 min and then incubated with KRBH containing
15 mM glucose for 30 min. GH was measured by an enzyme immunoassay
kit (Roche). Secretion was expressed as the percentage of GH release into
the medium relative to the total cellular GH content.
Immunoelectron microscopy
Immunoelectron microscopy was performed as described previously (Wada
and Kanwar, 1998). INS-1 cells were fixed with 0.1% paraformaldehyde and
0.05% glutaraldehyde in 0.01 M phosphate buffer (pH 7.4) for 30 min. After
the cells were scraped off the dish, a pellet was prepared with a Microfuge.
Then the pellet was dehydrated in a graded ethanol series and its tempera-
ture was gradually lowered to 220ºC. Stepwise infiltration was carried out
with Lowicryl-K4 medium and the cells were finally embedded in this low
temperature polymer resin. Uniform polymerization was carried out using ul-
traviolet light at a temperature below 220ºC for 24 hr and then at room tem-
perature for 48 hr. Approximately 60-nm sections were picked up on 300
mesh nickel grids. The sections were pretreated with 20 mM Tris-buffered
saline (pH 8.2) containing 0.25% bovine serum albumin, incubated with
anti-collectrin antibody, and then incubated with an anti-rabbit IgG conju-
gated with 15 nm colloidal gold particles for 4 hr at room temperature. The
sections were washed with Tris-buffered saline, stained with lead citrate
and uranyl acetate, and examined under an electron microscope at an accel-
erating voltage of 75 kV.
RIP-collectrin transgenic mice
Human myc-tagged collectrin cDNA was ligated to the rat insulin II promoter
containing the expression vector (Yamagata et al., 2002) and a 1.7-kb HindIII
expression unit was microinjected into the fertilized eggs of C57BL6 mice.
Age- and sex-matched transgene-negative littermates were used as con-
trols. For the glucose tolerance test, 24- to 28-week-old male mice were
fasted for 16 hr and then injected intraperitoneally with glucose (2 g/kg).
For perifusion experiments, 20 islets were perifused with Hepes-Krebs buffer
containing 0.5% BSA at a flow rate of 1 ml/min. The experimental protocol
was approved by the Ethics Review Committee for Animal Experimentation
of Osaka University.
Two-photon excitation imaging of exocytosis in pancreatic islets
Exocytosis of insulin granules was visualized in living pancreatic islets with
a solution containing a fluid-phase tracer (sulforhodamine B at 0.7 mM)
and 2-photon excitation imaging, as described previously (Takahashi et al.,
2002). To trigger the exocytosis of insulin by photolysis of a caged-Ca2+ com-
pound, islets were preincubated for 30 min at 37ºC in serum-free DMEM con-
taining 10 mM fura-2FF-AM (Tef Lab), 25 mM NP-EGTA-AM (Molecular
Probes), 0.03% crempho EL (Molecular probes), and 0.1% BSA (Takahashi
et al., 2004). Photolysis of NP-EGTA was induced with a brief flash (0.2-
0.5 s) of a mercury lamp. Exocytosis in response to 20 mM glucose or uncag-
ing of NP-EGTA was measured within an arbitrary area (2,000 mm2) of the
islets.
Yeast two-hybrid screening
The collectrin cDNA postsignaling sequence was subcloned in-frame into the
pGBKT7 bait vector (BD Biosciences Clontech) and transformed to yeast
AH109 (BD Biosciences Clontech). AH109 yeast was then mated at 30ºC
for 24 hr with Y187yeast that had been pretransformed with a human kidney
cDNA library (BD Biosciences Clontech). The mated yeasts were plated on
selection plates (SD/-Ade/-His/-Leu/-Trp) containing 2.5 mM 3-amino-1, 2,
4-triazole (3-AT). After 7-10 days, robust growing clones were picked up
and DNA was extracted. The DNA was transformed into Y187 yeast and
mated with AH109-collectrin again to confirm the interaction.
Immunoprecipitation and GST pull-down assay
Myc-tagged collectrin and HA-tagged snapin expression vectors were co-
transfected into 293 cells for 48 hr and the cells were lysed in a lysis buffer
containing 20 mM Tris-HCl (pH 7.5), 5 mM ethylenediaminetetraacetic acid
(EDTA), 10 mM Na4P2O7, 100 mM NaF, 2 mM Na3VO4, 1% NP-40, 1 mM phe-
nylmethylsulfonylfluoride (PMSF), 10 mg/ml aprotinin, and 10 mg/ml leupeptin.
The lysates were preincubated with protein G–Sepharose (Amersham Bio-
sciences) for 60 min and then incubated overnight with an anti-myc mouseCELL METABOLISM : DECEMBER 2005monoclonal antibody (9B11, Cell Signaling Technology, Beverly, MA), anti-
HA rabbit polyclonal antibody (Medical and Biological Laboratories, Nagoya,
Japan), or nonimmune serum at 4ºC. Immunoprecipitates were captured with
5% (v/v) protein G–Sepharose for 60 min and washed in the lysis buffer. Then
the immunoprecipitates were solubilized with sample buffer and subjected to
sodium dodecyl sulfate-polyacrylamide gel electrophoresis.
Full-length human collectrin and snapin cDNAs were generated by PCR
and cloned in-frame in the pGEX4T3 vector (Amersham). GST fusion proteins
were expressed and purified from E. coli BL21 (DE3). 35S-labeled syntaxin 1,
SNAP-25, VAMP2, collectrin, and snapin were synthesized using TNT quick
coupled transcription/ translation systems. Then the GST pull-down assay
was performed as described previously (Nishizawa et al. 2002).
Statistical analysis
All results were expressed as the mean6 SEM. Differences between groups
were examined for statistical significance using Student’s t- test and p < 0.05
was taken to indicate a significant difference.
Supplemental data
Supplemental Data include one figure, Supplemental Experimental Proce-
dures, and Supplemental References and can be found with this article online
at http://www.cellmetabolism.org/cgi/content/full/2/6/373/DC1/.
Acknowledgments
We thank Ms. F. Katsube and Dr. A. Ihara for their valuable help with this
study. We also thank Dr. R. Palmiter (University of Washington) for providing
the RIP expression vector, Dr. J. Miyazaki (Osaka University) for the gift of
MIN6 cells, and Dr. J.M. Zabolotny (Beth Israel Deaconess Medical Center)
for critical reading of the manuscript. This work was supported by grants
from the Ministry of Education, Culture, Sports, Science, and Technology
of Japan. The work of Drs. L.M. and G.C.W. was supported by grants from
the National Institute of Health (NIH NCRR ICR U4Z RR 16606 and
U19DK61251) and the Diabetes Research and Wellness Foundation. Drs
C.B.W. and H.W. were supported by the Swiss National Science Foundation
No 32-66907.01 and 32-66907.02.
Received: November 16, 2004
Revised: August 13, 2005
Accepted: November 3, 2005
Published: December 6, 2005
References
Bellanne-Chantelot, C., Chauveau, D., Gautier, J.F., Dubois-Laforgue, D.,
Clauin, S., Beaufils, S., Wilhelm, J.M., Boitard, C., Noel, L.H., Velho, G.,
and Timsit, J. (2004). Clinical spectrum associated with hepatocyte nuclear
factor-1b mutations. Ann. Intern. Med. 140, 510–517.
Buxton, P., Zhang, X.M., Walsh, B., Sriratana, A., Schenberg, I., Manickam,
E., and Rowe, T. (2003). Identification and characterization of Snapin as
a ubiquitously expressed SNARE-binding protein that interacts with
SNAP23 in non-neuronal cells. Biochem. J. 375, 433–440.
Cavaghan, M.K., Ehrmann, D.A., and Polonsky, K.S. (2000). Interactions be-
tween insulin resistance and insulin secretion in the development of glucose
intolerance. J. Clin. Invest. 106, 329–333.
Chen, Y.A., and Scheller, R.H. (2001). SNARE-mediated membrane fusion.
Nat. Rev. Mol. Cell Biol. 2, 98–106.
Chheda, M.G., Ashery, U., Thakur, P., Rettig, J., and Sheng, Z.H. (2001).
Phosphorylation of Snapin by PKA modulates its interaction with the SNARE
complex. Nat. Cell Biol. 3, 331–338.
Coppola, T., Perret-Menoud, V., Luthi, S., Farnsworth, C.C., Glomset, J.A.,
and Regazzi, R. (1999). Disruption of Rab3-calmodulin interaction, but not
other effector interactions, prevents Rab3 inhibition of exocytosis. EMBO
J. 18, 5885–5891.383
A R T I C L EDukes, I.D., Sreenan, S., Roe, M.W., Levisetti, M., Zhou, Y.P., Ostrega, D.,
Bell, G.I., Pontoglio, M., Yaniv, M., Philipson, L., and Polonsky, K.S. (1998).
Defective pancreatic b-cell glycolytic signaling in hepatocyte nuclear fac-
tor-1a-deficient mice. J. Biol. Chem. 273, 24457–24464.
Fajans, S.S., Bell, G.I., and Polonsky, K.S. (2001). Molecular mechanisms
and clinical pathophysiology of maturity-onset diabetes of the young.
N. Engl. J. Med. 345, 971–980.
Froguel, P., Zouali, H., Vionnet, N., Velho, G., Vaxillaire, M., Sun, F., Lesage,
S., Stoffel, M., Takeda, J., Passa, P., et al. (1993). Familial hyperglycemia due
to mutations in glucokinase: definition of a subtype of diabetes mellitus.
N. Engl. J. Med. 328, 697–702.
Horikawa, Y., Iwasaki, N., Hara, M., Furuta, H., Hinokio, Y., Cockburn, B.N.,
Lindner, T., Yamagata, K., Ogata, M., Tomonaga, O., et al. (1997). Mutation in
hepatocyte nuclear factor-1b gene (TCF2) associated with MODY. Nat.
Genet. 17, 384–385.
Iezzi, M., Regazzi, R., and Wollheim, C.B. (2000). The Rab3-interacting mol-
ecule RIM is expressed in pancreatic b-cells and is implicated in insulin exo-
cytosis. FEBS Lett. 474, 66–70.
Ilardi, J.M., Mochida, S., and Sheng, Z.H. (1999). Snapin: a SNARE-associ-
ated protein implicated in synaptic transmission. Nat. Neurosci. 2, 119–124.
Iwahashi, H., Yamagata, K., Yoshiuchi, I., Terasaki, J., Yang, Q., Fukui, K.,
Ihara, A., Zhu, Q., Asakura, T., Cao, Y., et al. (2002). Thyroid hormone recep-
tor interacting protein 3 (trip3) is a novel coactivator of hepatocyte nuclear
factor-4a. Diabetes 51, 910–914.
Jahn, R., Lang, T., and Sudhof, T.C. (2003). Membrane fusion. Cell 112, 519–
533.
Kasai, K., Ohara-Imaizumi, M., Takahashi, N., Mizutani, S., Zhao, S., Kikuta,
T., Kasai, H., Nagamatsu, S., Gomi, H., and Izumi, T. (2005). Rab27a medi-
ates the tight docking of insulin granules onto the plasma membrane during
glucose stimulation. J. Clin. Invest. 115, 388–396.
Lang, J. (1999). Molecular mechanisms and regulation of insulin exocytosis
as a paradigm of endocrine secretion. Eur. J. Biochem. 259, 3–17.
Lee, Y.H., Sauer, B., and Gonzalez, F.J. (1998). Laron dwarfism and non-
insulin-dependent diabetes mellitus in the Hnf-1alpha knockout mouse.
Mol. Cell. Biol. 18, 3059–3068.
Li, C., and Wong, W.H. (2001). Model-based analysis of oligonucleotide ar-
rays: expression index computation and outlier detection. Proc. Natl. Acad.
Sci. USA 98, 31–36.
Malecki, M.T., Jhala, U.S., Antonellis, A., Fields, L., Doria, A., Orban, T.,
Saad, M., Warram, J.H., Montminy, M., and Krolewski, A.S. (1999). Mutations
in NEUROD1 are associated with the development of type 2 diabetes melli-
tus. Nat. Genet. 23, 323–328.
Nishizawa, H., Yamagata, K., Shimomura, I., Takahashi, M., Kuriyama, H.,
Kishida, K., Hotta, K., Nagaretani, H., Maeda, N., Matsuda, M., et al.
(2002). Small heterodimer partner, an orphan nuclear receptor, augments
peroxisome proliferator-activated receptor g transactivation. J. Biol. Chem.
277, 1586–1592.
Nishizawa, H., Matsuda, M., Yamada, Y., Kawai, K., Suzuki, E., Makishima,
M., Kitamura, T., and Shimomura, I. (2004). Musclin, a novel skeletal mus-
cle-derived secretory factor. J. Biol. Chem. 279, 19391–19395.
Orci, L. (1974). A portrait of the pancreatic B-cell. Diabetologia 10, 163–187.
Pontoglio, M., Sreenan, S., Roe, M., Pugh, W., Ostrega, D., Doyen, A., Pick,
A.J., Baldwin, A., Velho, G., Froguel, P., et al. (1998). Defective insulin secre-
tion in hepatocyte nuclear factor 1a-deficient mice. J. Clin. Invest. 101, 2215–
2222.
Rorsman, P., and Renstro¨m, E. (2003). Insulin granule dynamics in pancreatic
beta cells. Diabetologia 46, 1029–1045.384Stoffers, D.A., Ferrer, J., Clarke, W.L., and Habener, J.F. (1997). Early-onset
type-II diabetes mellitus (MODY4) linked to IPF1. Nat. Genet. 17, 138–139.
Takahashi, N., Kishimoto, T., Nemoto, T., Kadowaki, T., and Kasai, H. (2002).
Fusion pore dynamics and insulin granule exocytosis in the pancreatic islet.
Science 297, 1349–1352.
Takahashi, N., Hatakeyama, H., Okado, H., Miwa, A., Kishimoto, T., Kojima,
T., Abe, T., and Kasai, H. (2004). Sequential exocytosis of insulin granules is
associated with redistribution of SNAP25. J. Cell Biol. 165, 255–262.
Tronche, F., Ringeisen, F., Blumenfeld, M., Yaniv, M., and Pontoglio, M.
(1997). Analysis of the distribution of binding sites for a tissue-specific tran-
scription factor in the vertebrate genome. J. Mol. Biol. 266, 231–245.
Vites, O., Rhee, J.S., Schwartz, M., Rosenmund, C., and Jahn, R. (2004). Re-
investigation of role of snapin in neurotransmitter release. J. Biol. Chem. 279,
26251–26256.
Wada, J., and Kanwar, Y.S. (1998). Characterization of mammalian translo-
case of inner mitochondrial membrane (Tim44) isolated from diabetic new-
born mouse kidney. Proc. Natl. Acad. Sci. USA 95, 144–149.
Wang, H., Maechler, P., Hagenfeldt, K.A., and Wollheim, C.B. (1998). Domi-
nant-negative suppression of HNF-1a function results in defective insulin
gene transcription and impaired metabolism-secretion coupling in a pancre-
atic b-cell line. EMBO J. 17, 6701–6713.
Wang, H., Antinozzi, P.A., Hagenfeldt, K.A., Maechler, P., and Wollheim, C.B.
(2000). Molecular targets of a human HNF1a mutation responsible for pan-
creatic b-cell dysfunction. EMBO J. 19, 4257–4264.
Winzell, M.S., and Ahren, B. (2004). The high-fat diet-fed mouse: a model for
studying mechanisms and treatment of impaired glucose tolerance and type
2 diabetes. Diabetes 53 (Suppl 3), S215–S219.
Wollheim, C.B. (2000). Beta-cell mitochondria in the regulation of insulin se-
cretion: a new culprit in type II diabetes. Diabetologia 43, 265–277.
Yamagata, K., Oda, N., Kaisaki, P.J., Menzel, S., Furuta, H., Vaxillaire, M.,
Southam, L., Cox, R.D., Lathrop, G.M., Boriraj, V.V., et al. (1996a). Mutations
in the hepatocyte nuclear factor-1a gene in maturity-onset diabetes of the
young (MODY3). Nature 384, 455–458.
Yamagata, K., Furuta, H., Oda, N., Kaisaki, P.J., Menzel, S., Cox, N.J., Fa-
jans, S.S., Signorini, S., Stoffel, M., and Bell, G.I. (1996b). Mutations in the he-
patocyte nuclear factor-4a gene in maturity-onset diabetes of the young
(MODY1). Nature 384, 458–460.
Yamagata, K., Yang, Q., Yamamoto, K., Iwahashi, H., Miyagawa, J., Okita,
K., Yoshiuchi, I., Miyazaki, J., Noguchi, T., Nakajima, H., et al. (1998). Muta-
tion P291fsinsC in the transcription factor hepatocyte nuclear factor-1a is
dominant negative. Diabetes 47, 1231–1235.
Yamagata, K., Nammo, T., Moriwaki, M., Ihara, A., Iizuka, K., Yang, Q., Satoh,
T., Li, M., Uenaka, R., Okita, K., et al. (2002). Overexpression of dominant-
negative mutant hepatocyte nuclear fctor-1a in pancreatic b-cells causes ab-
normal islet architecture with decreased expression of E-cadherin, reduced
b-cell proliferation, and diabetes. Diabetes 51, 114–123.
Yang, Q., Yamagata, K., Fukui, K., Cao, Y., Nammo, T., Iwahashi, H., Wang,
H., Matsumura, I., Hanafusa, T., Bucala, R., et al. (2002). Hepatocyte nuclear
factor-1amodulates pancreatic b-cell growth by regulating the expression of
insulin-like growth factor-1 in INS-1 cells. Diabetes 51, 1785–1792.
Yoshiuchi, I., Yamagata, K., Zhu, Q., Tamada, I., Takahashi, Y., Onigata, K.,
Takeda, J., Miyagawa, J., and Matsuzawa, Y. (2002). Identification of a gain-
of-function mutation in the HNF-1b gene in a Japanese family with MODY.
Diabetologia 45, 154–155.
Zhang, H., Wada, J., Hida, K., Tsuchiyama, Y., Hiragushi, K., Shikata, K.,
Wang, H., Lin, S., Kanwar, Y.S., and Makino, H. (2001). Collectrin, a collecting
duct-specific transmembrane glycoprotein, is a novel homolog of ACE2 and
is developmentally regulated in embryonic kidneys. J. Biol. Chem. 276,
17132–17139.CELL METABOLISM : DECEMBER 2005
